More than 30,000 people die each year from lung cancer in France, making it one of the deadliest cancers. Sometimes chemotherapy is not enough to save patients. A new treatment could improve its treatment: Sanofi announced this Thursday the suspension of the phase III clinical trial of Libtayo, which it is developing with Regeneron, in view of “a significant improvement in overall survival”.
Libtayo is a monoclonal antibody, i.e. a human immune cell reproduced in large quantities in the laboratory due to its action against a disease and which is then injected into patients. In the Phase III clinical trial, Sanofi tested this product in combination with a platinum-based chemotherapy doublet, commonly used to treat patients with non-small cell lung cancer (NSCLC) in the past. advanced stage.
The main endpoint of this new treatment was overall survival. However, the clinical trial quickly proved conclusive: the combination of Libtayo with chemotherapy allowed patients a median overall survival of 22 months, against 13 months for chemotherapy alone. Sanofi also claims a 29% reduction in the risk of death.
The clinical trial stopped prematurely
“This phase III trial included patients whose tumors exhibited features that complicate their treatment, as well as patients with locally advanced cancer,” said Dr. Miranda Gogishvili, oncologist at the High Technology Medical Center of the University Clinic of Tbilisi, Georgia, in a statement. These data add to the growing body of evidence supporting Libtayo’s interest in the treatment of advanced non-small cell lung cancer. “
On the recommendation of an independent committee responsible for monitoring the trial data, the experiment was therefore prematurely stopped. The data presented therefore relate to 466 patients. They should “form the basis of regulatory submissions to be presented in the United States and the European Union,” said Sanofi in its press release.
The treatment has already shown positive results against certain skin cancers and, more recently, uterine cancer. It has been approved in the European Union (EU) against these skin cancers and, in recent weeks, against lung cancers of the NSCLC type, a decision taken by Brussels even before the positive results announced on Thursday.